Sign in

IRMD on Nasdaq

IRADIMED CORP

American surgical and medical instruments and apparatus company2

In its 2026 annual report the company says: “We are the only known provider of a non-magnetic intravenous infusion pump system that is specifically designed to be safe for use during MRI procedures and operates dependably in magnetic fields up to 15,000 gauss. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures.”4 It is headquartered in Winter Park, United States.2 Its shares trade on Nasdaq under the symbol IRMD.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Delcath Systems, Inc., TELA Bio, Inc. or Pulmonx Corp, or pick any stock.

  • TickerIRMD on Nasdaq2
  • IndustrySurgical & Medical Instruments & Apparatus2
  • HeadquartersWinter Park, United States2
  • Incorporated inDE3
  • Business address12705 Ingenuity Drive, Orlando, Fl 328263
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300YVHWP0YJ1YW8162
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O Corporation Service Company, 19808 Wilmington, United States2

See how the biggest companies compare on our leaderboards

IRADIMED CORPORATION (“IRadimed”, the “Company,” “we,” “us,” “our” or similar terms) develops, manufactures, markets and distributes Magnetic Resonance Imaging (“MRI”) compatible medical devices and related accessories, disposables and services relating to them. We were originally incorporated in Oklahoma under the name IRI Development, Inc. in 1992, and we merged our Oklahoma corporation into the newly formed Delaware corporation, IRADIMED CORPORATION, in April 2014.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

76.7%Gross margin5
31.2%Operating margin5
26.8%Net margin5
14.4%Revenue growth, 20255
23.8%Return on equity5
$17.2MFree cash flow5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Regions

United States brought in 84% of the revenue IRADIMED CORP broke down this way in fiscal 2025.

  1. United States$70.6M584%up 16% from 2024
  2. Outside the United States$13.3M516%up 5% from 2024
Regions by year
Regions20242025
United States$60.6M$70.6M
Outside the United States$12.6M$13.3M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue23¢$19.5M
  • Research and development4¢$3.0M
  • Other costs39¢$33.0M
  • Income tax7¢$5.9M
  • Profit27¢$22.5M

Out of $83.8M in revenue.5

Where each dollar of operating cash went, fiscal 2025

  • Capital spending31¢$7.8M
  • Dividends paid60¢$15.0M
  • Kept or used elsewhere9¢$2.1M

Out of $24.9M of cash from operations.5

Financial statements

Revenue67895$83.8M in 2025+118% since 2019
0$25.0M$50.0M$75.0M$100.0M2019: $38.5M$38.5M20192020: $31.7M$31.7M2020−18%2021: $41.8M$41.8M2021+32%2022: $53.3M$53.3M2022+27%2023: $65.6M$65.6M2023+23%2024: $73.2M$73.2M2024+12%2025: $83.8M$83.8M2025+14%
Gross profit67895$64.3M in 2025+117% since 2019
0$20.0M$40.0M$60.0M$80.0M2019: $29.7M$29.7M20192020: $23.6M$23.6M2020−21%2021: $32.0M$32.0M2021+36%2022: $41.3M$41.3M2022+29%2023: $50.2M$50.2M2023+22%2024: $56.4M$56.4M2024+12%2025: $64.3M$64.3M2025+14%
Operating income67895$26.1M in 2025+202% since 2019
-$10.0M0$10.0M$20.0M$30.0M2019: $8.6M$8.6M20192020: -$756.1K-$756.1K20202021: $9.8M$9.8M20212022: $15.6M$15.6M2022+59%2023: $20.0M$20.0M2023+28%2024: $22.0M$22.0M2024+10%2025: $26.1M$26.1M2025+19%
Net income67895$22.5M in 2025+133% since 2019
0$10.0M$20.0M$30.0M2019: $9.6M$9.6M20192020: $1.4M$1.4M2020−86%2021: $9.3M$9.3M2021+581%2022: $12.8M$12.8M2022+38%2023: $17.2M$17.2M2023+34%2024: $19.2M$19.2M2024+12%2025: $22.5M$22.5M2025+17%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Revenue$83.8M$73.2M
Cost of revenue$19.5M$16.9M
Gross profit$64.3M$56.4M
General and administrative$17.8M$15.9M
Sales and marketing$17.4M$15.6M
Research and development$3.0M$2.8M
Total operating expenses$38.2M$34.4M
Income from operations$26.1M$22.0M
Other income, net$2.2M$2.3M
Income before provision for income taxes$28.4M$24.3M
Provision for income tax expense$5.9M$5.0M
Net income$22.5M$19.2M
Basic (in dollars per share)$1.77$1.52
Diluted (in dollars per share)$1.75$1.50
Basic (in shares)12.7M shares12.7M shares
Diluted (in shares)12.9M shares12.8M shares

Compare IRADIMED CORP with another company

Corporate structure

IRADIMED CORP sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of IRADIMED CORP

  • IRADIMED CORP Winter Park, Florida, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What IRADIMED CORP reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$28.9M5 Dec 31, 2025$21.4M5 Dec 31, 2024+35.1%
Accumulated depreciation$5.1M5 Dec 31, 2025$4.6M5 Dec 31, 2024+10.4%
Property and equipment, net$23.9M5 Dec 31, 2025$16.8M5 Dec 31, 2024+41.9%
Operating-lease assets (leased space)$154.7K9 Dec 31, 2024$2.0M9 Dec 31, 2023−92.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$51.2M5 Dec 31, 2025$52.2M5 Dec 31, 2024−2.1%

Intangibles and goodwill

ItemLatestA year beforeChange
Finite-lived intangibles, gross$4.9M5 Dec 31, 2025$4.3M5 Dec 31, 2024+15.3%
Accumulated amortization$1.6M5 Dec 31, 2025$1.2M5 Dec 31, 2024+31.3%
Finite-lived intangibles, net$3.4M5 Dec 31, 2025$3.1M5 Dec 31, 2024+9.2%

Inventory

ItemLatestA year beforeChange
Inventory, total$11.6M5 Dec 31, 2025$10.4M5 Dec 31, 2024+11.7%
Raw materials$9.6M5 Dec 31, 2025$9.0M5 Dec 31, 2024+6.5%
Work in process$831.0K5 Dec 31, 2025$568.0K5 Dec 31, 2024+46.3%
Finished goods$1.7M5 Dec 31, 2025$1.3M5 Dec 31, 2024+31.3%

Properties, in its own words

During the third quarter of 2025, the Company completed construction and took occupancy of its New Facility with approximately 62,000 square foot, corporate office and manufacturing facility in Orlando, Florida. The New Facility maintains the Company’s corporate headquarters and primary manufacturing operation in a single purpose-built location designed to support current operations and future growth. The Company funded the construction entirely with cash, and the property is wholly owned with no outstanding debt.

Prior to occupying the New Facility, the Company leased office and manufacturing space to support its operations during the first and second quarters of 2025. Following the completion of construction, the Company transitioned its operations to the New Facility in the third quarter of 2025 and the applicable leases were terminated in accordance with their contracts.

The rest of Item 2

The New Facility will accommodate the Company’s operational and manufacturing needs for the foreseeable future and provides available space and flexibility for growth and expansion.

Item 2 of the 10-K filed Mar 6, 2026.4

Leadership

Who has led IRADIMED CORP, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Roger E. Susi2014–now

Chair

  1. Roger E. Susi2016–now

President

  1. Roger E. Susi2014–now

Chief financial officer

  1. John Glenn2022–now

Chief operating officer

  1. John K. McCreery2017–2020
201520202025
Board members and other officers (14)

Timeline

  1. Aug 18, 20268-K Results of operations29
  2. Jul 31, 20268-K Other events30
  3. Jun 24, 20268-K Shareholder vote31
  4. May 1, 20268-K Results of operations32
  5. Feb 10, 20268-K Results of operations33
  6. Dec 8, 20258-K Other events34
  7. Nov 3, 20258-K Results of operations35
  8. Sep 2, 20258-K Executive or director change; Regulation FD disclosure36
  9. Aug 1, 20258-K Results of operations37
  10. Jun 23, 20258-K Shareholder vote38
  11. May 29, 20258-K Other events39
  12. May 5, 20258-K Results of operations40
  13. Jul 15, 2014New chief executive Roger E. Susi becomes CEO13

Calendar

Coming up

  1. Nov 2, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.43 a share, on Nov 3, 2025.41

When it reported results

  1. Aug 18, 2026Reported quarterly or annual results29
  2. May 1, 2026Reported quarterly or annual results32
  3. Feb 10, 2026Reported quarterly or annual results33
  4. Nov 3, 2025Reported quarterly or annual results35
  5. Aug 1, 2025Reported quarterly or annual results37
  6. May 5, 2025Reported quarterly or annual results40
  7. Feb 13, 2025Reported quarterly or annual results42
  8. Jan 10, 2025Reported quarterly or annual results43

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

318 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 45 major events, 193 insider forms, 18 large holders, 41 other. The latest 20:

  1. Sep 25, 20264 EDGAR
  2. Sep 8, 20264 EDGAR
  3. Sep 3, 2026144 EDGAR
  4. Aug 18, 20268-K/A EDGAR
  5. Jul 31, 202610-Q EDGAR
  6. Jul 31, 20268-K EDGAR
  7. Jul 28, 2026SCHEDULE 13G EDGAR
  8. Jun 24, 20268-K EDGAR
  9. Jun 23, 20264 EDGAR
  10. Jun 4, 20264 EDGAR
  11. Jun 4, 2026144 EDGAR
  12. Jun 2, 20264 EDGAR
  13. May 28, 20264 EDGAR
  14. May 20, 20264 EDGAR
  15. May 14, 2026SCHEDULE 13G/A EDGAR
  16. May 13, 20264 EDGAR
  17. May 6, 20264 EDGAR
  18. May 1, 202610-Q EDGAR
  19. May 1, 20268-K EDGAR
  20. Apr 30, 2026ARS EDGAR

The 318 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

189 open-market trades by officers, directors and large owners since October 2021: 0 buys and 189 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 3, 2026ALLEN MONTY KDirectorSale1,419$86.41$122.6KForm 4
Jun 4, 2026Scharen-Guivel Hilda FrederiqueDirectorSale3,000$95.00$285.0KForm 4
Jun 1, 2026Susi Roger E.CEO, President, ChairmanSale2,500$90.60$226.5KForm 4
May 27, 2026Susi Roger E.CEO, President, ChairmanSale2,500$91.95$229.9KForm 4
May 26, 2026Susi Roger E.CEO, President, ChairmanSale5,000$92.23$461.2KForm 4
May 19, 2026Susi Roger E.CEO, President, ChairmanSale2,500$87.88$219.7KForm 4
May 18, 2026Susi Roger E.CEO, President, ChairmanSale5,000$87.51$437.6KForm 4
May 12, 2026Susi Roger E.CEO, President, ChairmanSale4,411$83.92$370.2KForm 4
May 11, 2026Susi Roger E.CEO, President, ChairmanSale3,089$84.54$261.2KForm 4
May 5, 2026Susi Roger E.CEO, President, ChairmanSale3,750$85.74$321.5KForm 4
May 4, 2026Susi Roger E.CEO, President, ChairmanSale3,750$85.69$321.3KForm 4
Apr 28, 2026Susi Roger E.CEO, President, ChairmanSale3,750$86.23$323.4KForm 4
Apr 27, 2026Susi Roger E.CEO, President, ChairmanSale3,750$89.16$334.3KForm 4
Apr 21, 2026Susi Roger E.CEO, President, ChairmanSale2,500$90.94$227.3KForm 4
Apr 20, 2026Susi Roger E.CEO, President, ChairmanSale5,000$93.36$466.8KForm 4
Apr 14, 2026Susi Roger E.CEO, President, ChairmanSale2,500$93.84$234.6KForm 4
Apr 13, 2026Susi Roger E.CEO, President, ChairmanSale5,000$92.52$462.6KForm 4
Apr 7, 2026Susi Roger E.CEO, President, ChairmanSale2,500$94.84$237.1KForm 4
Apr 6, 2026Susi Roger E.CEO, President, ChairmanSale5,000$96.02$480.1KForm 4
Mar 30, 2026Susi Roger E.CEO, President, ChairmanSale7,500$95.02$712.6KForm 4

All 189 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Roger Susi$385.6K$780.6K49
2025John Glenn$378.9K$610.0K49
2025Jeffrey Chiprin$205.0K$529.4K49
2024Chief Financial Officer$350.4K$1.3M49
2024President and Chief Executive Officer$337.4K$689.6K49

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.967,825$92.5M0.0%+38
Kayne Anderson Rudnick Investment Management LLC396,982$37.9M0.1%+47,666
Renaissance Technologies LLC394,412$37.7M0.1%−46,300
Copeland Capital Management, LLC391,860$37.4M0.8%+32,535
Vanguard Capital Management LLC364,937$34.9M0.0%+6,317
Geode Capital Management, LLC290,109$27.7M0.0%+3,546
Nine Ten Capital Management LLC256,562$24.5M7.6%−77,926
Dimensional Fund Advisors LP229,340$21.9M0.0%+3,194
State Street Corp221,512$21.2M0.0%+16,984
Goldman Sachs Group Inc214,151$20.5M0.0%+16,206
Two Sigma Investments, LP182,894$17.5M0.0%+17,225
Qube Research & Technologies Ltd157,199$15.0M0.0%+73,750
Royal Bank Of Canada148,179$14.2M0.0%+118,371
Arrowstreet Capital, Limited Partnership143,969$13.8M0.0%+128,524
Northern Trust Corp133,658$12.8M0.0%+10,022
Morgan Stanley126,051$12.0M0.0%−23,788
Vanguard Portfolio Management LLC125,357$12.0M0.0%+2,932
Ranger Investment Management, L.P.98,346$9.4M0.6%−12,739
Russell Investments Group, Ltd.94,982$9.1M0.0%−4,516
First Trust Advisors LP84,318$8.1M0.0%+81,977
Shaker Investments Llc/oh81,641$7.8M2.8%+21,601
Envestnet Asset Management Inc78,559$7.5M0.0%+3,099
Bank of New York Mellon Corp75,885$7.3M0.0%−3,992
Granahan Investment Management, LLC74,966$7.2M0.3%+70,066
Algert Global LLC72,994$7.0M0.1%−15,062

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How IRADIMED CORP is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARIRADIMED CORP1
  • CIK0001325618
  • Employer ID (EIN)73-14085264
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address12705 Ingenuity Drive, Orlando, FL 328261
  • Phone40767780221
  • Shares outstanding12,786,991 as of Jul 31, 202611
  • Public float$480.9M as of Jun 30, 20254
  • AuditorRSM US LLP, Orlando, Florida PCAOB ID 49; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceApr 25, 20051
  • Filings774 in all: 4 (458), 8-K (119), 10-Q (37), 144 (24), 3 (18), 10-K (12), DEF 14A (11), 4/A (10)1
    All 38 form types

    CORRESP (10), SC 13G/A (10), UPLOAD (9), SC 13G (7), DEFA14A (4), EFFECT (4), ARS (3), S-1/A (3), S-3 (3), S-8 (3), SCHEDULE 13G/A (3), 10-K/A (2), 10-Q/A (2), 424B5 (2), 8-K/A (2), DRSLTR (2), S-3/A (2), SCHEDULE 13G (2), 3/A (1), 424B4 (1), 8-A12B (1), CERTNAS (1), CT ORDER (1), DEF 14C (1), DRS (1), DRS/A (1), PRE 14C (1), REGDEX (1), S-1 (1), S-1MEF (1)

  • Latest filingsAnnual report (10-K) Mar 6, 2026
    Quarterly report (10-Q) Jul 31, 2026
    Proxy statement (DEF 14A) Apr 30, 2026
    Latest 8-K (8-K) Jul 31, 2026

Securities registered for trading

ClassSymbolExchange
Common stock, par value $0.0001 per shareIRMDNasdaq

From the cover page of the 10-K filed Mar 6, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks IRADIMED CORP names in Item 1A of its 10-K filed Mar 6, 2026: 38 risks under these headings, as written.4

  • Risks Relating to Our Business and Financial Condition
  • Our financial performance is significantly dependent on a limited number of products, and disruptions in our ability to sell these products may have a material adverse effect on our business.
  • Our continued success depends on the integrity of our supply chain and unaffiliated third-party suppliers for certain of our raw materials and components, the disruption of which could negatively impact our business.
  • A cybersecurity incident or failure to protect our information technology infrastructure could be disruptive to our business, compromise confidential data, cause reputation harm, adversely affect our business and operating results, subject us to litigation and federal and state governmental inquiries.
  • The manufacture of our products requires strict adherence to regulatory requirements governing medical devices and if we or our suppliers encounter problems our business could suffer.
  • Our markets are very competitive, and we sell certain of our products in a mature market.
  • We manufacture and store our products at a single facility in Florida.
  • If we fail to maintain relationships with IDNs and GPOs, sales of our products could decline.
  • The lengthy sales cycle for medical devices could delay our sales.
  • Because we rely on distributors to sell our products outside of the U.S., our revenues could decline if our existing distributors do not continue to purchase products from us or if our relationship with any of these distributors is terminated.
  • If we do not successfully develop and commercialize enhanced products or new products that remain competitive, we could lose revenue opportunities and customers, and our ability to achieve growth would be impaired.
  • We are highly dependent on our founder, Chairman of the Board of Directors, President and Chief Executive Officer, Roger Susi.
The other 27 risks
  • We may be unable to scale our operations successfully.
  • The environment in which we operate makes it difficult to accurately forecast our business performance.
  • There are inherent uncertainties involved in estimates, judgments and assumptions used in the preparation of financial statements in accordance with U.S. GAAP. Furthermore, portions of U.S. GAAP require the use of fair value models which are variable in application and methodology from appraiser to appraiser. Any changes in estimates, judgments and assumptions used could have a material adverse effect on our business, financial position, and operating results.
  • Changes in effective tax rates or adverse outcomes resulting from examination of our income or other tax returns could adversely affect our results.
  • The constant growth and development of technology, including the increased use of AI, presents
  • risks and challenges to our operations that could give rise to legal or regulatory action, damage our reputation or otherwise materially harm of our business.
  • Our financial condition, results of operations and cash flow may be adversely affected by changing economic
  • conditions, including interest rates and inflation, and other factors beyond our control.
  • Risks Related to Our Industry
  • We are subject to substantial government regulation and trade policies that are subject to change and could force us to make modifications to how we develop, manufacture, market, and price our products.
  • If we fail to obtain, or experience significant delays in obtaining, FDA clearances or other necessary approvals to commercially distribute new products, our ability to maintain profitability or grow will suffer.
  • We are subject to risks associated with doing business outside of the U.S.
  • We may incur product liability losses or become subject to other lawsuits related to our products, business, and insurance coverage could be inadequate or unavailable to cover these losses.
  • Our products or product types, or MR imaging could be subject to negative publicity, which could have a material adverse effect on our financial position and results of operations and could cause the market value of our common stock to decline.
  • U.S. healthcare policy and changes thereto, including the Patient Protection and Affordable Care Act, may have a material adverse effect on our financial condition and results of operations.
  • We are subject to healthcare fraud and abuse regulations that could result in significant liability, require us to change our business practices and restrict our operations in the future.
  • We could be adversely affected by violations of the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws.
  • We and our suppliers and customers are required to obtain regulatory approvals and maintain compliance with regulations applicable to medical devices, including infusion pumps and patient monitors, and these approvals could result in delays or increased costs in developing new products, subject us to sanctions and could adversely affect our business.
  • Risks Relating to our Intellectual Property
  • Our success depends on our ability to protect our intellectual property, unpatented trade secrets, know-how, confidential and proprietary information, and technology.
  • There can be no assurance of timely patent review and approval that would minimize competition and allow us to generate sufficient revenues.
  • We may become involved in patent litigation or other intellectual property proceedings relating to our current and future product clearances, which could result in liability for damages or delay or stop our development and commercialization efforts.
  • Risks Related to Ownership of Our Common Stock
  • Our common stock price has been and will likely continue to be subject to significant fluctuations and volatility, and you may be unable to sell your shares at a fair price, or at all.
  • Any use of capital to repurchase shares of our common stock, need to or choice to raise future capital, the election to continue, reduce or cease to pay a regular cash dividend, could have a material adverse effect on our stock price and our business.
  • The requirements of being a public company may strain our resources, divert management’s attention and affect our ability to attract and retain executive management and qualified Board members.
  • Roger Susi, who serves as our Chairman of the Board of Directors, President and Chief Executive Officer, owns a significant percentage of our stock and will be able to exert significant influence over matters subject to stockholder approval.
  • Our business practices are more visible as a public company, and this could impact our competitive environment and risk of potential litigation or involvement in securities class action litigation that could adversely affect our business and could subject us to significant liabilities.
  • If securities or industry analysts do not publish research or reports about our business, or if they publish unfavorable research or downgrade our stock, our stock price and trading volume could decline.
  • Our charter documents and Delaware law have provisions that may discourage an acquisition of us by others and may prevent attempts by our stockholders to replace or remove our current management.

Legal proceedings

From time to time, we are involved in legal proceedings arising in the ordinary course of business, including proceedings for which we may not have insurance coverage. While many of these matters involve inherent uncertainty as of the date hereof, we do not currently believe that any such legal proceedings will have a material adverse effect on our business, financial position, results of operations or liquidity. We also believe that adequate reserves for these liabilities have been made.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
    SEC EDGAROther events
  31. 31
  32. 32
  33. 33
  34. 34
    SEC EDGAROther events
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
    SEC EDGAROther events
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49